AHA Science
@ahascience
The official account for American Heart Association meetings, science news, funding opportunities and membership.
Join us at #Hypertension26 in Arlington, Virginia! Learn more about the new CKM guideline in clinical practice and connect with peers at the Innovations in Clinical Care Reception. ⏳ Aug. 24 is the last day to receive the Advance Registration Discount. Register today: https://bit.ly/4fiIdRH
Picture your research alongside leaders in the stroke and brain health medicine. Submit your abstract by Aug. 18. That moment starts at #ISC27. 🧠 #ISC27Chair: Marion S. Buckwalter, MD, PhD Submit your science: https://bit.ly/4fcO3mj
Imagine your work in the room with leaders advancing stroke and brain health science. 🧠 Step into the spotlight at #ISC27. 🗓️Submit your abstract by Aug. 18. Submit your science: https://bit.ly/4fcO3mj
The 2026 Guideline on the Management of Dyslipidemia was recently published. Here are the top things for clinicians using PREVENT-ASCVD Equations for Risk-Based Lipid Management.
The 2026 Guideline on the Management of Dyslipidemia was recently published. Here are the top things for women’s health clinicians to know.
The 2026 Guideline on the Management of Dyslipidemia was recently published. Here are the top things for geriatric clinicians to know.
The 2026 Guideline on the Management of Dyslipidemia was recently published. Here are the top things for pediatric clinicians to know.
The 2026 Guideline on the Management of Dyslipidemia was recently published. Here are the top 10 things for health care professionals to know.
That’s a wrap on #EpiLifestyle26! Thanks to everyone who helped take this meeting to a whole new level. Let’s meet again at #EpiLifestyle27 📅 March 2-5, 2027 📍 Boston, Massachusetts
Meet the authors of the 2026 ACC/AHA Dyslipidemia Guideline! Join us at 8 a.m. Thursday for an in-depth discussion of the updated recommendations in the new guideline – an update to the 2018 joint cholesterol guideline – and their implications for clinical practice. #EPILifestyle26
Welcome to Boston and #EPILifestyle26! Hit repost and share the big moments you’re looking forward to most. Let’s make this week unforgettable, together.
Fuel your discoveries with funding, mentorship and the powerful research network of the American Heart Association. We’re here to help you thrive.
From bold ideas to lifesaving breakthroughs, your research starts here. Grant applications are open to help you shape the future of health.
Fuel your discoveries with funding, mentorship and the powerful research network of the American Heart Association. Don’t miss a chance to advance science and save lives. Applications are open.
It’s not too late to save your spot for #ISC26! Be part of this global gathering of experts changing the future of stroke and brain health science. See you in New Orleans in 50 days!
Your research has the power to save lives. An American Heart Research Awards gives you the support to make it happen. Applications are open!
ICYMI here are results from all 17 LBS presentations at #AHA25. Missed them? Check them out on Scientific Sessions OnDemand coming in early December.
Advance your research with the support you deserve. We anticipate that about 1,000 grants will be awarded this year to help you advance science and save lives. Applications are open now.
The TOP trial is a parallel, single-blind, randomized, clinical superiority trial, N=1424 that sought to determine whether liberal versus restrictive transfusion strategy after major general and vascular surgery reduces adverse outcomes in high cardiac risk patients. Sunil Rao, MD on the results.
ANGPTL3, presented at #AHA25 showed gene editing demonstrates few adverse events. More from Dr. Harrington👇👇
Calling all coffee drinkers! Dr. Khan has good news from the DECAF trial presented at #AHA25. ☕☕☕
What is the potential clinical impact of the OPTIMA trial? Here is one prediction. #AHA25
In patients with AF who are stable beyond one year of drug-eluding stent implantation NOAC monotherapy provides a simple and safe long-term therapy versus combination therapy.
📢 Adding evolocumab to lipid-lowering therapy significantly reduced the risk of a first major CV event in patients without prior heart attack or stroke. #AHA25 ⬇️
The study demonstrates that DR10624 can lead to significant reductions in triglycerides with favorable safety and tolerability results. Shayan Mohammadmoradi's, MS, PhD take on the data presented at #AHA25
